Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

ts are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether experimental pain models of pain, including the capsaicin model, are accurate in predicting efficacy of novel analgesics in early clinical trials, whether the results of any Phase II trial or other study of NGX426 will be consistent with the results of the study reported in this press release, whether TorreyPines will be able to complete any potential strategic or financing transaction on terms acceptable to TorreyPines' stockholders, how the volatile economic environment will affect TorreyPines' efforts to complete a strategic or financing transaction, whether TorreyPines' cash resources will be sufficient to fund operations as planned, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical tri
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... and its potential to revolutionize the world has ... multinational corporations and small start-ups. The early years ... research projects largely due to the high risks ... Government budgets earmarked for this evolving technology have ...
(Date:9/19/2014)... SAN FRANCISCO , Sept. 19, 2014 /PRNewswire/ ... announced results from preclinical studies characterizing the analgesic ... oral, peripherally-acting kappa opioid receptor agonist molecules. The ... molecule polymer medicinal chemistry platform. The ... described in the medical literature. 1,2 Kappa ...
(Date:9/19/2014)... 19, 2014 Barnhardt Manufacturing Company ... for its Organic Cotton . The USDA Certified ... renewable biobased ingredients meets or exceeds levels set by ... in whole or in significant part of agricultural, forestry, ... our Organic cotton to be immediately identified as a ...
(Date:9/19/2014)... -- , The first grants awarded to ... (ESPE) Meeting  Investment supports innovative projects for ... field of growth  , EMD Serono, a ... , today announced the first recipients of the Grant ... announced during a Satellite Symposium organized by EMD Serono ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... , , HUNTERSVILLE, N.C., ... leader in built-in antimicrobial product protection, has partnered with YogaDirect.com, ... the U.S., to launch the first ever line of yoga ... of yoga mats that will stay cleaner and fresher for ...
... , DOYLESTOWN, Pa., July 28 ... company to offer a broad range of accredited CME courses in ... clinical trials. , , The comprehensive education and ... Institute (BRITI)(TM). RadMD is partnering with International Center for Postgraduate Medical ...
... , , WESTFORD, Mass., July ... manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial ... Second Quarter 2009 Financial Results , , ... with $39.2 million in the same period of 2008 and $14.8 million in ...
Cached Biology Technology:Microban Partners With YogaDirect.com to Launch Yoga Mats With Zinc Antimicrobial Technology 2RadMD First to Offer CME-Certified Education and Training For Medical Imaging in Clinical Trials 2Cynosure Reports Second Quarter 2009 Financial Results 2Cynosure Reports Second Quarter 2009 Financial Results 3Cynosure Reports Second Quarter 2009 Financial Results 4Cynosure Reports Second Quarter 2009 Financial Results 5Cynosure Reports Second Quarter 2009 Financial Results 6Cynosure Reports Second Quarter 2009 Financial Results 7Cynosure Reports Second Quarter 2009 Financial Results 8Cynosure Reports Second Quarter 2009 Financial Results 9Cynosure Reports Second Quarter 2009 Financial Results 10Cynosure Reports Second Quarter 2009 Financial Results 11Cynosure Reports Second Quarter 2009 Financial Results 12Cynosure Reports Second Quarter 2009 Financial Results 13
(Date:9/18/2014)... researchers from McGill University and the Quebec government ... ,microbeads, Canadian Journal of Fisheries and Aquatic ... cosmetics, household cleansers, or industrial cleansers, to which ... their small size and buoyancy, they may readily ... a global contaminant in the world,s oceans, but ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, it,s ... creatures. , But by using a signaling ... alter their behavior to suit their population. In ... are present, and act accordingly. , Once the ... may change from innocuous to pathogenic, or from ...
(Date:9/18/2014)... language is unique to humans. "The genetic changes that ... evolution to make this possible are largely unknown, but ... says Wolfgang Enard, Professor of Anthropology and Human Biology ... biological basis of language Enard has now taken an ... undertaken in collaboration with scientists at several universities, including ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... University Feinberg School of Medicine played a significant ... Abraxane (paclitaxel protein-bound particles for injectable suspension), indicated ... approval means that women with metastatic breast cancer ... with solvents and will no longer need steroid ...
... In laboratory mouse experiments, researchers at The University of ... way to use RNA interference (RNAi) so that it ... activated STAT3, a crucial gene found in some human ... invasive. , The study, presented at the annual meeting ...
... provide for study of human immune responses, scientists have ... rapid immune response by two separate armies of defensive ... microbes like the leprosy bug, this initial defense sometimes ... yields to a dangerous, spreading infection. , Led by ...
Cached Biology News:Nanoparticle Breast Cancer Drug Approved by FDA 2Used in a new way, RNA interference permanently silences key breast cancer gene 2Leprosy microbes lead scientists to immune discovery 2
... The four-bay DNA Engine Tetrad ... of interchangeable Alpha units (sample-holder, heat-pump ... numbers of vessels. A Pentium-class computer ... displays current block, sample, and lid ...
Printer paper for Model 680 series readers is used with the thermal printers of the Model 680 and Model 680 XR microplate readers. Supplied as 2 rolls....
... for 2-D separations. The cell has a six-gel ... xi multi-cell can be customized for several parameters: ... cooling system. The PROTEAN II xi multi-cell can ... multi-cell for a wider format that accommodates 17 ...
... is tailored to highly enrich ... rat spleen cells. Cells are ... compatible 0.5 Tesla) immunomagnetic negative ... content of the enriched fraction ...
Biology Products: